Sarah Caddick joins the Center for Accelerating Medical Solutions of Washington, DC, as executive vice president. The Center, a new initiative of the Milken Institute, is an independent organization established this spring to examine the entire medical research and treatment process. Caddick comes to CAMS from the Wadsworth Foundation, an organization dedicated to finding a cure for multiple sclerosis, where she had been executive director. Prior to joining the foundation, she was the director of medical and scientific programs for the Steve and Michele Kirsch Foundation, and before that, director of award programs at the Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation. She currently serves as a member of the research advisory board for the National Center for Sleep Disorder Research at the National Institutes of Health. Caddick holds a PhD in neuroscience from the University of Southampton, UK, and a BSc in biology from the University of Portsmouth, UK.
Chris Rivera joins Seattle’s Corixa as vice president of sales. Previously, he served as vice president of business development at GeneCraft. In a 20-year career, Rivera has worked at Genzyme Therapeutics, Genzyme Tissue Repair, Cephalon, Centocor, and the Bristol-Myers Squibb company.
Dana Fowlkes was elected chairman of the board of directors at Hemocellular Therapeutics, a North Carolina biotech that uses technologies licensed from the University of North Carolina and East Carolina University. Kenneth Lee was elected vice chairman.
Craig Venter will join Ionian Technologies’ board of directors, the Upland, Calif., company said. Venter, the former CSO and founder of Celera Genomics, currently heads three non-profits that he founded: The Center for the Advancement of Genomics; the Institute for Biological Energy Alternatives; and the Craig Venter Science Foundation. He is also founder and chairman of The Institute for Genomic Research in Rockville, Md. Ionian Technologies develops molecular diagnostics tools.
Kevin Starr has been appointed to the board of directors of Alnylam, the Cambridge, Mass., RNA interference therapeutics company said. Starr is the former chief operating officer and CFO of Millennium Pharmaceuticals, where he worked from 1998 through December 2002.